Search bioRxiv⌕ Search

Biology subjects

Pye, R. J.

Publications and source records attributed to Pye, R. J..

5 recordsLinked to original sources
bioRxiv2026

Ethyl-iophenoxic acid as a serum biomarker for marsupial species in oral bait trials

Ethyl-iophenoxic acid (Et-IPA) is widely recognized as a useful biomarker to confirm oral bait consumption in eutherian species. In historical studies on marsupials, Et-IPA was rapidly eliminated from brushtail possums (Trichosurus vulpecula) and swamp wallabies (Wallabia bicolor) suggesting limited use for marsupial species. However, a 1 mg oral dose of Et-IPA was detectable in the marsupial Tasmanian devils (Sarcophilus harrisii) for [≥] 56 days suggesting the biomarker can be used in a devil bait vaccine program. To assess Et-IPA marking in off-target marsupials that may consume baits, we administered 1 mg oral doses of Et-IPA to brushtail possums, forester kangaroos (Macropus giganteus tasmaniensis), spotted-tailed quolls (Dasyurus maculatus) and eastern quolls (Dasyurus viverrinus). Liquid chromatography with tandem mass spectrometry was used to detect and quantify serum Et-IPA. Et-IPA was detected in the serum on day 2 but was not detected by day 14 in any of the species tested, including the two quoll species which are in the same carnivorous Dasyuridae family as the devils. The rapid elimination of Et-IPA in the marsupials included in this study suggests it is not useful as a biomarker for these species. Furthermore, rapid elimination in the kangaroos and possums suggests that Et-IPA is unlikely to accumulate in the food chain following distribution of Et-IPA-marked oral bait vaccines for Tasmanian devils. Short summary for non-expertsA recent study in Tasmanian devils (Sarcophilus harrisii) challenged the concept that ethyl iophenoxic acid (Et-IPA) is not a useful serum biomarker for marsupials. Using the same sensitive liquid chromatography-tandem mass spectrometry method we detected serum Et-IPA in four marsupial species on day two post-ingestion but by day 14, serum Et-IPA was undetectable. These findings indicate that Et-IPA is an unsuitable biomarker for these species and suggest that Et-IPA from devil bait vaccines is unlikely to bioaccumulate in the Tasmanian environment.

zoology↗
bioRxiv2022

Evaluation of oral baits and distribution methods for Tasmanian devils (Sarcophilus harrisii)

ContextDiseases are increasingly contributing to wildlife population declines. Tasmanian devil (Sarcophilus harrisii) populations have locally declined by 82% largely due to the morbidity and mortality associated with two independent transmissible devil facial tumours (DFT1 and DFT2). Toxic baits are often used as a management tool for controlling vertebrate pest populations in Australia, but in other areas of the world oral baits are also used to deliver vaccines or pharmaceuticals to wildlife. Oral vaccine bait products have been distributed for more than 50 years at a landscape scale to protect wildlife from rabies virus and contributed to the elimination of fox rabies from more than ten European nations. An oral bait vaccine to protect against devil facial tumours has been proposed as a management tool to improve the population health, resiliency and fitness of wild Tasmanian devils. AimOur goal was to evaluate the potential use of edible baits as vehicles for vaccine delivery to Tasmanian devils. MethodWe tested placebo versions of baits that are already used in Australia. Key resultsCaptive devils consumed all types of placebo baits but exhibited a preference for ruminant- and fish-based baits. Captive devils also consumed inert capsules inserted into placebo baits. Bait fate trials in the field revealed that baits were generally removed within 24 hours. Tasmanian pademelons (Thylogale billardierii), brushtail possums (Trichosurus vulpecula), and Eastern quolls (Dasyurus viverrinus) were the most common nontarget bait competitors at six private properties in southern Tasmania; wild devils removed approximately 5% of ground baits at these sites. We also evaluated an automated bait dispenser, which reduced nontarget uptake and resulted in over 50% of the baits being removed by devils. ConclusionsThis study demonstrates that captive and wild devils will accept and consume placebo versions of commercial baits. Bait dispensers or modified baits or baiting strategies are needed to increase bait uptake by devils. ImplicationsBait dispensers can be used at a regional scale to deliver baits to Tasmanian devils. These could act as vehicles for preventive or therapeutic vaccines to mitigate the impacts of disease on devil populations. Short summaryThis study aimed to test oral baits as potential vaccine delivery vehicles for Tasmanian devils. Captive and wild devils consumed placebo versions of commercial baits used on mainland Australia. Abundant non-target species, such as brushtail possums, Tasmanian pademelons, and eastern quolls consumed most baits in the wild. Implementation of automated bait dispensers increased bait uptake by devils to over 50% at the same regional field sites.

zoology↗
bioRxiv2021

Cathelicidin-3 associated with serum extracellular vesicles enables early diagnosis of a transmissible cancer

The identification of practical early diagnosis biomarkers is a cornerstone of improved prevention and treatment of cancers. Such a case is devil facial tumour disease (DFTD), a highly lethal transmissible cancer afflicting virtually an entire species, the Tasmanian devil (Sarcophilus harrisii). Despite a latent period that can exceed one year, to date DFTD diagnosis requires visual identification of tumour lesions. To enable earlier diagnosis, which is essential for the implementation of effective conservation strategies, we analysed the extracellular vesicle (EV) proteome of 87 Tasmanian devil serum samples. The antimicrobial peptide cathelicidin-3 (CATH3) was enriched in serum EVs of both devils with clinical DFTD (87.9% sensitivity and 94.1% specificity) and devils with latent infection (i.e., collected while overtly healthy, but 3-6 months before subsequent DFTD diagnosis; 93.8% sensitivity and 94.1% specificity). As antimicrobial peptides can play a variety of roles in the cancer process, our results suggest that the specific elevation of serum EV-associated CATH3 may be mechanistically involved in DFTD pathogenesis. This EV-based approach to biomarker discovery is directly applicable to improving understanding and diagnosis of a broad range of diseases in other species, and these findings directly enhance the capacity of conservation strategies to ensure the viability of the imperilled Tasmanian devil population.

cancer biology↗
bioRxiv2018

Tasman-PCR: A genetic diagnostic assay for Tasmanian devil facial tumour diseases

Tasmanian devils have spawned two transmissible cancer clones, known as devil facial tumour 1 (DFT1) and devil facial tumour 2 (DFT2). DFT1 and DFT2 are transmitted between animals by the transfer of allogeneic contagious cancer cells by biting, and both cause facial tumours. DFT1 and DFT2 tumours are grossly indistinguishable, but can be differentiated using histopathology, cytogenetics or genotyping of polymorphic markers. However, standard diagnostic methods require specialist skills and equipment and entail long processing times. Here, we describe Tasman-PCR: a simple PCR-based diagnostic assay that distinguishes DFT1 and DFT2 by amplification of DNA spanning tumour-specific interchromosomal translocations. We demonstrate the high sensitivity and specificity of this assay by testing DNA from 557 tumours and 818 normal devils. A temporal-spatial screen confirmed the reported geographic ranges of DFT1 and DFT2 and did not provide evidence of additional DFT clones. DFT2 affects disproportionately more males than females, and devils can be co-infected with DFT1 and DFT2. Overall, we present a PCR-based assay that delivers rapid, accurate and high-throughput diagnosis of DFT1 and DFT2. This tool provides an additional resource for devil disease management and may assist with ongoing conservation efforts.

genetics↗